NASDAQ:AMYT - Nasdaq - US03217L1061 - ADR - Currency: USD
/PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and...
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 22,...
A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares.
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage...
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 ...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!
Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma (AMYT) for total transaction value of ~$1.25B in upfront consideration, representing a 107% premium to Amryt ADS' closing price on...
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - Transaction expands Chiesi’s rare disease medicine...
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt...
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors DUBLIN,...
European Commission approves Mycapssa® for the treatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU ...